Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients.
Fiche publication
Date publication
septembre 2019
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François
Tous les auteurs :
Calugareanu A, Jachiet M, Tauber M, Nosbaum A, Aubin F, Misery L, Droitcourt C, Barbarot S, Debarbieux S, Saussine A, Bagot M, de Masson A, Sénéschal J, Staumont-Sallé, Bouaziz JD,
Lien Pubmed
Résumé
Prurigo nodularis (PN) is a debilitating pruritic skin condition with an unmet therapeutic need (1). The mechanisms triggering PN are still unknown. Studies suggest the implication of the Th2 cytokine pathway (interleukin 4 (IL-4) and interleukin 13 (IL-13)) in its pathogenesis (2), evidenced by recent monocentric case series showing the efficacy of IL-4 and IL-13 blocker (dupilumab) for PN treatment (3-8).
Mots clés
atopic dermatitis, conjunctivitis, dupilumab, eosinophilia, prurigo nodularis
Référence
J Eur Acad Dermatol Venereol. 2019 Sep 17;: